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Abstract: Therapeutic targeting of estrogen receptor-α (ERα) by the anti-estrogen tamoxifen is standard
of care for premenopausal breast cancer patients and remains a key component of treatment strategies for
postmenopausal patients. While tamoxifen significantly increases overall survival, tamoxifen resistance
remains a major limitation despite continued expression of ERα in resistant tumors. Previous reports
have described increased oxidative stress in tamoxifen resistant versus sensitive breast cancer and
a role for PARP1 in mediating oxidative damage repair. We hypothesized that PARP1 activity
mediated tamoxifen resistance in ERα-positive breast cancer and that combining the antiestrogen
tamoxifen with a PARP1 inhibitor (PARPi) would sensitize tamoxifen resistant cells to tamoxifen therapy.
In tamoxifen-resistant vs. -sensitive breast cancer cells, oxidative stress and PARP1 overexpression were
increased. Furthermore, differential PARylation of ERα was observed in tamoxifen-resistant versus
-sensitive cells, and ERα PARylation was increased by tamoxifen treatment. Loss of ERα PARylation
following treatment with a PARP inhibitor (talazoparib) augmented tamoxifen sensitivity and decreased
localization of both ERα and PARP1 to ERα-target genes. Co-administration of talazoparib plus
tamoxifen increased DNA damage accumulation and decreased cell survival in a dose-dependent
manner. The ability of PARPi to overcome tamoxifen resistance was dependent on ERα, as lack of
ERα-mediated estrogen signaling expression and showed no response to tamoxifen-PARPi treatment.
These results correlate ERα PARylation with tamoxifen resistance and indicate a novel mechanism-based
approach to overcome tamoxifen resistance in ER+ breast cancer.
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1. Introduction
Estrogen receptor-α (ERα) is a nuclear receptor [1–3] that responds to estrogen stimulation by
translocating to the nucleus and regulating the transcription of target genes, including ERα and
genes involved in regulating tumor progression [4]. Nearly 70% of breast cancers express ERα
and rely on estrogen binding for growth and promotion of tumorigenesis [4]. Many ERα+ breast
cancer patients are treated with the anti-estrogen tamoxifen, which binds to the receptor within
the ligand-binding domain (LBD). Mechanistically, binding of tamoxifen to the receptor results in a
conformational change, initially decreasing the capacity of ERα to engage target genes. Aside from
the tamoxifen-ERα interaction, tamoxifen-induced oxidative damage was reported to be an integral
component of its therapeutic efficacy [5–7], through increased reactive oxygen species (ROS), and
blocking ROS activity reduced anti-estrogen sensitivity [8]. Although highly effective in ER+ breast
cancers, many of these patients develop resistance to tamoxifen, relapse and eventually succumb to
the disease, despite continued ERα expression in their tumors [9]. In this regard, a better underlying
mechanisms mediating tamoxifen resistance is of foremost clinical significance [10].
Endocrine resistance evolves from many mechanisms, including altered epigenetic regulation [11–13],
as well as post-translational modifications (PTMs) of ERα [10,14,15]. Many PTMs modify the ability
of ERα to interact with transcriptional cofactors and engage target gene sequences in response to
tamoxifen therapy, shifting tamoxifen from an antagonist to an ERα agonist [15]. In this context,
additional understanding of ERα regulation may help identify novel approaches to overcome
tamoxifen resistance in the presence of persistent ERα expression.
Poly (ADP-ribose) polymerase 1 (PARP1) is a nuclear enzyme [16] that regulates cell signaling
and the DNA damage response by poly-ADP-ribosylating (PARylating) target proteins, including
PARP1 itself [17,18]. A critical role for PARP1 in tumor progression through regulation of oxidative
DNA damage has been demonstrated and indicated as a mechanism to overcome PARPi resistance
[19,20]. Classically, clinical applications of PARP inhibitors (PARPi), such as talazoparib and veliparib,
target BRCA-related cancers with defects in HR-mediated DNA repair pathways [21–23]. In addition
to DNA damage, PARP1 regulates the activity of many nuclear receptors, including ERα [24]. It was
revealed in a breast cancer model (MCF7, ERα-positive) that in response to estradiol, ERα and PARP1
co-localize to ERα-target genes to regulate their expression [25]. Furthermore, in vascular smooth muscle
cells, ERα was demonstrated to be PARylated by PARP1 within the DNA binding domain (DBD),
allowing for increased and maintained nuclear localization of ERα [26]. However, whether or not ERα is
PARylated in breast cancer cells, and if PARylation correlates with tamoxifen response, is unknown.
Based on previous reports demonstrating elevated oxidative stress in ERα-positive, tamoxifen resistant
breast cancer [5,8,27] and the role of PARP1 in responding to oxidative damage [28,29], we hypothesized
that combining the antiestrogen tamoxifen with a PARPi would sensitize tamoxifen resistant, ERα-positive
breast cancer to tamoxifen therapy. We tested our hypothesis in a MCF7-based breast cancer cell model
systems. Combining a PARPi with tamoxifen altered ERα PARylation and decreased ERα-PARylation, and
this was sufficient to overcome tamoxifen resistance in hormone-refractory, ERα-positive breast cancer cells.
Our results demonstrate a novel mechanism of resistance to antiestrogen therapy and support a therapeutic
approach for overcoming endocrine-resistant, ERα-positive breast cancer.
2. Results
2.1. Survival of Tamoxifen-Sensitive and -Resistant Breast Cancer Cells Is Inhibited by Tamoxifen-Talazoparib
Combination
We observed that tamoxifen-resistant (MCF7-T) cells showed increased levels of oxidative
damage (Figure 1A), as indicated by immunofluorescence staining for the oxidative-damage marker
8-hydroxyguanosine (8-oxoG), consistent with previous studies [27] and validated this observation by
measuring basal levels of reactive oxygen species (ROS) in tamoxifen-sensitive versus -resistant cell
lines. As indicated by immunofluorescence, we observed increased (p < 0.05) levels of ROS in MCF7-T
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cells compared to the MCF7 parental cells (Figure 1B). We and others have demonstrated that oxidative
damage caused by ROS promotes PARP1 activation [28,29]. We measured PARP1 levels and activity
(indicated by poly-(ADP)-ribosylation (PARylation)), using western blot and ELISA assays and observed
that basal PARP1 levels and activity were higher in MCF7-T cells compared to MCF7 cells (Figure 1C
and Supplemental Figure S1A), as well as active ERBB2 (pERBB2), a marker of tamoxifen resistance [30].
Furthermore, tamoxifen treatment increased (p < 0.05) PARP1 activity in both parental and resistant cell
lines (Figure 1D; ELISA assay).
Figure 1. Therapeutic inhibition of PARP1 promotes sensitivity to tamoxifen treatment, in ER+ breast
cancer, scale bar: 20 µm. (A) Immunofluorescence staining of 8-hydroxyguanosine (8-oxoG) in MCF7 and
MCF7-T cell lines. (B) Basal ROS levels in MCF7 compared MCF7-T cells. Quantification is representative
of at least three individual experiments. (C) MCF7 and MCF7-T cells were treated for 24 h with 100 nM
tamoxifen (Tamox) and western blot analysis performed against the indicated antibodies. (D) MCF7 and
MCF7-T cells were treated with Tamox (24 h, 100 nM) and subjected to PAR ELISA (E) MCF7 and MCF7-T
cells were treated with 100 nM Tamox or 1 nM Talaz for 72 h, alone and in combination, and colony
formation assay was performed. (F) MCF7 (Top) and MCF7-T (Bottom) cells were treated with Tamox
and Talaz for 72 h, alone and in combination, and subjected to clonogenic survival assay to determine
drug efficacy; x-axis is indicative of Fraction affected (FA), y-axis is indicative of the combination
index (CI). Combinations beneath the black dashed line are synergistic. Results are representative of
three independent experiments. (G) MCF7 and MCF7-T cells were treated with 100 nM Tamox or 10 nM
veliparib (Velip) for 72 h, alone and in combination, and colony formation assay was performed. PAR, Poly
(ADP-ribose). ** p < 0.001, *** p < 0.0001 compared to control, # p < 0.01, ## p < 0.001, ### p < 0.0001
relative to bracketed treatment.
Cancers 2019, 11, 43 4 of 19
To examine whether PARP1 inhibition altered cell sensitivity to tamoxifen, we treated MCF7
and MCF7-T cells with tamoxifen alone or in combination with talazoparib and performed colony
formation assays. As expected, tamoxifen alone decreased (p < 0.05) MCF7 clonogenic survival,
and increased (p < 0.05) MCF7-T cell clonogenicity (Figure 1E). Despite differential response to
tamoxifen, co-administration of tamoxifen and talazoparib decreased (p < 0.05) cell survival in both
MCF7 and MCF7-T cells (Figure 1E, Supplemental Figure S1B,C). The observed decrease in colony
formation was synergistic (CI < 1) (Figure 1F, Supplemental Figure S1B,C), as determined by the
Chou-Talalay method [31]. Similar combinatorial efficacy was observed upon co-administration of
tamoxifen with the less potent PARPi veliparib (Velip; Figure 1G) [32].
To confirm the combinatorial efficacy of tamoxifen and talazoparib was not limited to the
tamoxifen-resistant cells examined, we performed clonogenic survival assays in independently derived
tamoxifen-resistant, ERα+ breast cancer cell lines (LCC2, LCC9; ref [33]). Treatment of LCC2 and
LCC9 with tamoxifen-talazoparib decreased (p < 0.05) cell survival (CI < 1; Supplemental Figure S1D,E,
respectively). Furthermore, PARP1 activity was increased (p < 0.05) in LCC2 and LCC9 cell lines
compared to MCF7 parental cells (Supplemental Figure S1F) and tamoxifen further increased (p < 0.05)
PARP1 activity (Supplemental Figure S1G).
To validate the observed decrease in colony formation by MCF7 and MCF7-T cells in
anchorage-dependent growth conditions, survival was also measured under anchorage-independent
conditions. Both MCF7 and MCF7-T cells were plated within an agarose substrate and treated with
tamoxifen in the presence and absence of talazoparib. Consistently, tamoxifen alone decreased (p < 0.05)
MCF7 cell survival, while combination tamoxifen-talazoparib further decreased (p < 0.05) both MCF7
and MCF7-T survival compared to control or either single agent (Supplemental Figure S2A).
2.2. Tamoxifen-Talazoparib Combinatorial Efficacy Is ERα-Dependent
To determine whether response to the combination was dependent on ERα, we treated
MDA-MB-231 cells (TNBC; negative for ER, PR and HER2) and MCF7-F (clonally derived,
fulvestrant resistant and lack ERα signaling; [30]) with tamoxifen in the presence and absence
of PARPi, and performed colony formation assays. In response to tamoxifen alone, no effect on
cell survival was observed in either cell line (Supplemental Figure S2B–D), as expected. Similarly,
following co-administration of tamoxifen with PARPi, no increase in cell response to tamoxifen
treatment was observed. Fulvestrant treatment with or without talazoparib had no effect on MCF7-F
cell survival (Supplemental Figure S2C,D).
In response to tamoxifen treatment, ERα was shown to translocate to the nucleus in
tamoxifen-resistant cells, with cytoplasmic localization being indicative of tamoxifen sensitivity [34].
In this regard, we observed tamoxifen treatment alone increased ERα nuclear localization
(Supplemental Figure S3), consistent with previous reports [34], and co-administration with talazoparib
increased both PARP1 and ERα cytoplasmic subcellular localization (caveolin-1 (Cav1) was used to
validate decreased ERα function; [35]). Based on these results, it was next of interest to further examine a
role for PARP1 in mediating tamoxifen resistance.
2.3. Tamoxifen-Talazoparib Co-Administration Increases Cellular DNA Damage
Inhibition of PARP1 using clinical PARPi increases DNA double strand break (DSB) repair in
BRCA-proficient cells, which can be assessed by RAD51 foci formation [36]. To examine whether
altered DSB repair contributed to talazoparib-mediated tamoxifen sensitivity, we measured RAD51
foci formation in both MCF7 and MCF7-T cells following treatment with talazoparib in the presence
and absence of tamoxifen. In response to talazoparib treatment alone, we observed increased (p < 0.05)
RAD51 foci in both MCF7 and MCF7-T cell lines (Figure 2A–C), consistent with the synthetic lethal
relationship between PARP and BRCA-mediated DNA damage repair [21,22]. Interestingly, tamoxifen
treatment alone did not alter RAD51 foci formation compared to control, and tamoxifen-talazoparib
co-administration had no effect on RAD51 foci formation compared to talazoparib alone (Figure 2A–C).
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Figure 2. Tamoxifen-talazoparib co-administration induces DNA damage but not RAD51 foci formation.
(A) MCF7 and (B) MCF7-T cells were treated with either 100 nM tamoxifen (Tamox) or 1 nM talazoparib
(Talaz) for 72 h, alone and in combination. 24 h post treatment RAD51 foci formation assay was
performed. Scale bar: 20 µm. (C) Quantification is representative of three individual experiments.
(D) MCF7 and (E) MCF7-T cells were treated with 100 nM Tamox, with and without 1 nM Talaz for
48 h. 24 h post treatment cells immunofluorescence staining for γH2 AX was performed. Scale bar:
20 µm. (F) Quantification is representative of three independent experiments. * p < 0.001, *** p < 0.0001
compared to control, # p < 0.01, ## p < 0.001 relative to bracketed treatment.
Because no specific effect on RAD51 was observed, we next examined DNA damage more
generally. MCF7 and MCF7-T cells were treated with tamoxifen in the presence and absence of
talazoparib, and immunofluorescence staining for γH2Ax foci formation was performed. In response
to tamoxifen alone, we observed increased (p < 0.05) γH2Ax staining, which was further increased
(p < 0.05) by co-administration with talazoparib (Figure 2D–F). These findings are consistent with a
previous study by Qi et al. showing that tamoxifen can impair homologous recombination repair,
while promoting DNA damage accumulation [37].
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2.4. Tamoxifen Induces ROS, and ROS Promotes PARylaton of ERα
Because co-administration of tamoxifen and PARPi increased both tamoxifen response and
γH2AX foci, but not RAD51 foci formation, it was of interest to further investigate the mechanism
of PARPi-mediated tamoxifen sensitivity. We previously observed that basal ROS is increased in
tamoxifen-resistant versus sensitive breast cancer cells (Figure 1A,B). Tamoxifen treatment increases
intracellular ROS, and increased ROS is an important determinant of tamoxifen efficacy [5,8]. Based on
these reports and our observations (Figure 2D–F), we tested whether tamoxifen increased oxidative
damage and if tamoxifen-mediated ROS increased PARP1 activity. MCF7 and MCF7-T cells were
treated with increasing concentrations of tamoxifen, and ROS levels were measured. We observed
that tamoxifen increased (p < 0.05) ROS in a dose-dependent manner (Figure 3A), consistent with
previous reports [5,8]. Furthermore, MCF7 and MCF7-T cells were treated with tamoxifen in the
presence and absence of the ROS scavenger N-acetyl-L-cysteine (NAC) and cells were subjected
to both immunofluorescence staining against 8-oxoG and western blot analysis. In response to
tamoxifen, increased 8-oxoG staining was observed, which diminished upon co-administration
with NAC (Figure 3B). Western blot analysis revealed increased PAR levels following tamoxifen
treatment (Figure 3C and shown in Figure 1D), and co-administration with NAC decreased (p < 0.05)
PAR levels (Figure 3C). Taken together, these data suggest tamoxifen increases PARP1 activity in a
ROS-dependent manner.
Upon ROS-induced activation, PARP1 PARylates associated proteins to regulate cellular response
to oxidative damage [28]. Moreover, in a vascular smooth muscle cell model [26], it was demonstrated
that PARP1 PARylated ERα, resulting in altered ERα nuclear translocation, response to ligand
and transcriptional activity. PARP1 activity has been shown to be an important regulator of ERα
function [26]; however, whether ERα PARylation is involved in breast cancer and furthermore
tamoxifen resistance has not been examined. To initially test if ERα was PARylated and whether
ROS promoted ERα PARylation, we treated MCF7-T cells with H2O2 (2 mM for 3 h) and subsequently
immunoprecipitated ERα. Following addition of H2O2 (oxidative damage conditions), we observed
increased ERα PARylation and an increased ERα-PARP1 interaction (Figure 3D). To examine whether
ERα was differentially PARylated in tamoxifen-sensitive versus -resistant breast cancer cells, ERα was
immunoprecipitated in untreated MCF7 and MCF7-T cells, and PAR accumulation was examined by
western blot analysis. Interestingly, we observed greater interaction between ERα and PAR in the
tamoxifen-resistant MCF7-T cell line compared to the sensitive MCF7 cells (Figure 3E). These results
demonstrate that oxidative damage is sufficient to promote ERα PARylation in breast cancer and
correlate ERα PARylation with tamoxifen resistance.
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Figure 3. Tamoxifen-induced ROS accumulation promotes ERα PARylation. (A) MCF7 and MCF7-T
cells were treated with the increasing concentrations of tamoxifen (Tamox) for 4 h, and subjected to ROS
assay. (B) MCF7 and MCF7-T cells were treated with Tamox (1 µM) in the presence and absence of 1 mM
N-acetyl-L-cysteine (NAC). 24 h post treatment immunofluorescence staining of 8-hydroxyguanosine
(8-oxoG) was performed. Results are representative of three independent experiments, and quantified
below. Scale bar: 20 µm. (C) MCF7 and MCF7-T cells were treated with 100 nM Tamox with or
without 1 mM NAC (ROS scavenger). 24 h post treatment cell lysates were subjected to western blot
analysis. (D) MCF7-T cells were treated with 2 mM H2O2 for 4 h. Treated cells were subjected to
immunoprecipitation (ERα) and western blot analysis against the indicated antibodies. (E) MCF7
and MCF7-T subjected to immunoprecipitation (ERα) and western blot analysis against the indicated
antibodies. (F) MCF7-T cells were treated for 4 h with 100 nM Tamox with or without 1 nM talazoparib
(Talaz; pre-treat 24 h). Post treatment cells subjected to immunoprecipitation and western blot analysis
against the indicated antibodies. * p < 0.01, ** p < 0.001, *** p < 0.0001 compared to control, # p < 0.01, ##
p < 0.001 relative to bracketed treatment.
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2.5. Tamoxifen Promotes PARylation of ERα and PARylation Mediates ERα Response
We next hypothesized that tamoxifen-dependent ROS accumulation would likewise promote ERα
PARylation. We treated both MCF7 and MCF7-T cells with tamoxifen, in the presence and absence of
PARPi talazoparib and immunoprecipitated either ERα or PARP1 (MCF7-T cells). In response to tamoxifen
treatment, we observed increased ERα PARylation in both MCF7 (Supplemental Figure S4A) and MCF7-T
(Figure 3F) cells, and co-administration with talazoparib decreased the ERα PARylation, as well as the
interaction with PARP1. Based on these results, we suggest that loss of ERα PARylation by PARPi
treatment correlates with ERα response to ligands and increased cell sensitivity to antiestrogen therapy.
ERα is rapidly degraded in response to estradiol (E2) in breast cancer cells that are
tamoxifen-responsive [30]. However, in tamoxifen resistant cells, E2 does not induce ERα
degradation [30,33]. To validate that loss of PARP1 activity could mediate ERα response to
ligand, we treated cells with E2 and performed western blot analysis. As a positive control,
MCF7 cells were treated with E2 and reduced ERα levels were observed (Supplemental Figure S4B).
In contrast, E2 did not decrease ERα protein levels in MCF7-T cells (Supplemental Figure S4C),
whereas addition of the pure anti-estrogen fulvestrant markedly downregulated ERα protein levels
(Supplemental Figure S4D). Next, MCF7-T cells were treated with talazoparib alone or in combination
with E2, and under these conditions, a reduced level of ERα was observed (Supplemental Figure S4C).
These results suggest that PARPi is able to regulate ERα response to ligand as a function of PARP1
activity, consistent with previous observations [25,26].
2.6. Talazoparib Reduces PARP1 and ERα Localization to ERα Target Genes
Tamoxifen increased PARP1 activity, as well as ERα PARylation, and we observed that inhibition of
PARP1 activity decreased nuclear ERα localization (Supplemental Figure S3). We then explored the role
of PARP1 activity in regulating the enrichment of ERα at the promoter of ERα target genes. Based on
ERα-binding sites of previously identified ERα target genes, described by Jin et al., we performed
PARP1 chromatin immunoprecipitation (ChIP) analysis against a panel of genes (RARα, MYC, GREB1,
ERBB2, FOS, and XBP1) [4]. As a positive control, we also performed ERα ChIP against the same gene
panel. As predicted, treatment with talazoparib in both the tamoxifen-sensitive (MCF7) and -resistant
(MCF7-T) cell lines resulted in decreased (p < 0.05) recruitment of PARP1 to ERα-binding sites in the
majority of genes examined (Figure 4A,B). To a greater extent, ERα localization to ERα-binding sites
was likewise decreased (p < 0.05) following tamoxifen-talazoparib treatment relative to tamoxifen
treatment alone (Figure 4C,D). These results suggest that the ERα-PAR/PARP1 interaction is an
important regulator of ERα-localization to ERα target genes.
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Figure 4. Talazoparib decreases PARP1 and ERα localization to ERα-target genes. Chromatin
immunoprecipitation (ChIP) analysis of PARP1 localization to ERα-target genes (RARA, MYC, GREB1,
ERBB2, FOS, XBP1) was performed in (A) MCF7 or (B) MCF7-T cells following tamoxifen treatment
(Tamox; 100 nM) with or without talazoparib (Talaz; 1 nM). Chromatin immunoprecipitation (ChIP)
analysis of ERα localization to ERα-target genes (RARA, MYC, GREB1, ERBB2, FOS, XBP1) was
performed in (C) MCF7 or (D) MCF7-T cells following Tamox treatment (100 nM) with or without
1 nM Talaz. * p < 0.01, ** p < 0.001, *** p < 0.0001 compared to control.
2.7. Overexpression of miR-222 in Tamoxifen Resistant Cells Promotes PARP1 Activation
While we demonstrated that tamoxifen increased ERα PARylation, we also observed that the
basal ERα PARylation was increased in tamoxifen resistant versus sensitive cells (Figure 3E). As such,
it was of interest to investigate the mechanism by which PARP1 was overexpressed in tamoxifen
resistant breast cancer cells. It was recently demonstrated that microRNA-222 (miR-222) can both
increase PARP1 activity, and promote PARPi sensitivity in ovarian cancer cells [38]. We and others
demonstrated that miR-222 is overexpressed in tamoxifen resistant breast cancer cells compared
to their sensitive counterparts [39–41]. To validate that miR-222 was overexpressed in tamoxifen
resistant breast cancer, we measured basal miR-222 expression in parental MCF7 cells compared to
MCF7-T by qRT-PCR analysis. We observed increased (p < 0.05; ~6.5-fold) miR-222 expression in
tamoxifen resistant cells compared to the parental MCF7 cell line (Figure 5A). It was next of interest
to determine whether tamoxifen could increase miR-222 expression and to test whether miR-222
overexpression was sufficient to promote tamoxifen resistance. MCF7 cells were treated with tamoxifen
and qRT-PCR analysis was performed. As expected, tamoxifen treatment increased (p < 0.05) miR-222
expression in a dose-dependent manner (Figure 5B). We then treated MCF7 cells with tamoxifen in
the presence and absence of miR-222 overexpression and subjected cells to clonogenic survival assays.
In the absence of miR-222 overexpression, a dose-dependent decrease (p < 0.05) in cell survival was
observed, and subsequent addition of miR-222 prevented tamoxifen-mediated cell death (Figure 5C).
Consistently, we observed decreased (p < 0.05) cell survival in MCF7-T cells upon inhibition of miR-222
and treatment with tamoxifen (Supplemental Figure S5 and Figure 5D).
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Figure 5. miR-222 mediates ER response to tamoxifen, and tamoxifen-mediated PARP1 activation.
(A) Basal miR-222 expression was measured in MCF7 and MCF7-T cells by qRT-PCR analysis. (B) MCF7
and MCF7T cells were treated for 4 h with 100 nM tamoxifen (Tamox) and miR-222 expression was
measured by qRT-PCR analysis. (C) MC7 cells were treated with the indicated concentration of Tamox
for 4 h, with or without miR-222 overexpression. Treated cells were subjected to colony formation assays.
Quantification is representative of three independent experiments. (D) MCF7-T cells were treated 72 h
with 100 nM Tamox with or without miR-222 inhibition (KD). Treated cells were subjected to colony
formation assays. Quantification is representative of three independent experiments. (E) MCF7-T
cells were treated for 4 h with 100 nM Tamox with or without miR-222 inhibition. Post treatment
cells were subjected to PAR ELISA. Quantification is representative of three independent experiments.
(F) miR-222 was overexpressed in MCF7 cells and cell lysates subjected to qRT-PCR and western blot
analysis. * p < 0.01, ** p < 0.001, *** p < 0.0001 compared to control, # p < 0.01, ## p < 0.001 relative to
bracketed treatment.
Given that tamoxifen was sufficient to increase both PARP1 activity and miR-222 expression,
we determined whether tamoxifen-mediated PARP1 activation was miR-222 dependent. MCF7 cells
were treated with tamoxifen in the presence and absence of miR-222 inhibitor and measured PAR levels.
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We observed that tamoxifen treatment increased (p < 0.05) PARP1 activity, as previously demonstrated,
and subsequent inhibition of miR-222 decreased tamoxifen-mediated PARP1 activation (Figure 5E).
Regulation of PARP1 by miR-222 has been studied in depth in ovarian cancer cells [38];
however, whether miR-222 is sufficient to increase PARP1 activity in breast cancer is unknown.
Using a miR-222 mimic, we exogenously expressed miR-222 in MCF7 tamoxifen-sensitive cells and
measured PARP1 and PAR levels by western blot analysis. qRT-PCR validated overexpression of miR-222
(p < 0.05; ~3-fold) (Figure 5F). Furthermore, overexpression of miR-222 increased both PARP1 and PAR
levels (Figure 5F).
2.8. miR-222 Regulates the Response to Tamoxifen-PARPi Co-Administration
Because miR-222 overexpression increased PARP1 activity (Figure 5F), it was of interest to
measure the effect on RAD51 foci formation. Consistent with our observation (Figure 2A–C),
talazoparib treatment increased (p < 0.05) RAD51 foci in both MCF7 and MCF7-T cells (Figure 6A,B).
Additionally, overexpression of miR-222 blocked formation of talazoparib-mediated RAD51 foci,
irrespective of tamoxifen sensitivity (Figure 6A,B). We next investigated whether miR-222 mediated
the PARPi response and, more importantly, the response to tamoxifen-talazoparib co-administration.
First, we treated MCF7 cells with PARPi alone or combination with tamoxifen, in the presence and
absence of miR-222 overexpression, and subjected cells to colony formation assays. In MCF7 cells
overexpressing miR-222, we observed increased (p < 0.05) sensitivity to PARPi treatment (Figure 6C).
Second, to determine whether miR-222 mediated the tamoxifen-talazoparib response, MCF7-T cells
were treated with tamoxifen and increasing concentrations of talazoparib, with or without miR-222
expression. As miR-222 loss promoted sensitivity to tamoxifen (Figure 5D), tamoxifen-treated
cells were used as the control (Figure 6D). In the presence of miR-222 (control), we observed a
dose-dependent decrease in cell survival following tamoxifen-talazoparib co-administration; however,
miR-222 inhibition diminished tamoxifen-talazoparib mediated cell death (Figure 6D). Taken together,
our results support a role for talazoparib-mediated tamoxifen response in ER+, tamoxifen-resistant
breast cancer.
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Figure 6. Tamoxifen-induced miR-222 expression mediates sensitivity to tamoxifen-talazoparib
co-administration. (A) MCF7 and (B) MCF7-Tcells were treated with 1 nM talazoparib (Talaz) for
48 h in the presence or absence of miR-222 overexpression (O/E). Post treatment cells were subjected
to RAD51 foci formation assay. Quantification is representative of three independent experiments.
Scale bar: 20 µm. (C) MCF7 cells were treated with increasing concentrations of Talaz for 48 h, with or
without miR-222 overexpression. Post treatment cells were subjected to colony formation assays.
Quantification is representative of three independent experiments. (D) MCF7T cells were treated
with 100 nM tamoxifen (Tamox) and increasing concentration of Talaz for 48 h, with or without
miR-222 inhibition. Post treatment cells were subjected to colony formation assays. Quantification
is representative of three independent experiments. ** p < 0.001, *** p < 0.0001 compared to control,
# p < 0.01, ## p < 0.001 relative to bracketed treatment.
3. Discussion
Most breast tumors express ERα, and stimulation of ERα by estradiol plays a significant role in
breast tumor progression ERα-targeted therapies including tamoxifen demonstrate exceptional clinical
efficacy in treating breast cancer [42]. However, due to long-term treatment, resistance to tamoxifen
therapy is common, even though most resistant tumors continue to express ERα [4]. Mechanisms of
resistance include epigenetic alterations [11,41] and post-translational modifications [14], which alter
the antagonistic effects of tamoxifen on ERα function. Attempts to overcome tamoxifen resistance
through development of novel therapies that target estrogen synthesis [15,43,44], and combination
therapies have met with limited success, signifying a need to further explore therapeutic options to
overcome tamoxifen resistance. In this regard, our study reveals that both oxidative damage and
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PARP1 levels are elevated in ERα+ tamoxifen resistant breast cancer. Addition of a PARPi increases
cell response to tamoxifen therapy in an ERα-dependent manner. Through in vitro analysis, we show
that combining tamoxifen with talazoparib increases both DNA damage and PAR accumulation and
decreases survival of tamoxifen-resistant breast cancer cells. We identify miR-222 as a mediator of
tamoxifen and PARPi response as well as the efficacy of tamoxifen-talazoparib combination. The results
of this study support further investigation into combining antiestrogen with PARPi as a potential
therapeutic option to overcome tamoxifen resistance in ERα+ breast cancer.
Elevated levels of oxidative stress in tamoxifen resistant breast cancer have been previously
reported [27], which we postulate may correlate with increased PARP1 expression and activity,
implicating PARP1 as a therapeutic target to overcome tamoxifen resistance [19,20]. With respect
to our overall hypothesis, we demonstrate that intracellular ROS levels are elevated in tamoxifen
resistant versus sensitive cells, as are PARP1 levels and activity. Based on overexpression of PARP1,
we show co-administration of PARPi with tamoxifen decreases cell survival in ER+ breast cancer
cells. However, in breast cancer cells that do not depend on estrogen signaling for the survival
(MDA-MB-231, MCF7-F), the combination had no effect, demonstrating that ERα expression is integral
in mediating tamoxifen-talazoparib induced cell death. Additionally, treatment with the PARPi alone
increases DSB break repair, as indicated by increased RAD51 foci formation. However, tamoxifen alone
or in combination with PARPi had no effect on RAD51 foci formation. An increase in γH2AX following
tamoxifen and tamoxifen-talazoparib treatment further supports the notion that tamoxifen-talazoparib
induces DNA damage.
In addition to inhibiting ERα function, tamoxifen-induced intracellular ROS contributes to its
therapeutic efficacy [5]. Interestingly, increased oxidative damage has been hypothesized to act as a
mechanism to overcome PARPi resistance and a distinct therapeutic vulnerability in cancer cells [19,45].
In support of these studies, we demonstrate that tamoxifen treatment increases ROS accumulation
in both MCF7 and MCF7-T cell lines, and tamoxifen-mediated ROS accumulation is sufficient to
promote PARP1 activation. Inversely, ROS depletion following tamoxifen treatment diminishes PARP1
activity. We posit that tamoxifen treatment results in PARP1 activation and ultimately PARPi-tamoxifen
response in a ROS-dependent manner.
Our results relate ROS accumulation by tamoxifen to increase ERα PARylation. PARP1 regulates
cell signaling, including DNA damage response, through rapid PARylation of target proteins,
including PARP1 itself [24]. In vascular smooth muscle cells, ERα is directly PARylated by PARP1,
altering the ability of ERα to bind its target genes [26]. To our knowledge, this is the first
demonstration that ERα is PARylated in breast cancer cells and that tamoxifen can induce ERα PARylation.
Moreover, treatment with talazoparib diminishes ERα PARylation, as well as the interaction between
ERα and PARP1, which correlates with talazoparib-mediated tamoxifen response. Differential ERα
PARylation in tamoxifen sensitive versus resistant cells correlates with tamoxifen sensitivity. As ERα
functions as a nuclear receptor and a transcription factor, talazoparib treatment decreases both PARP1 and
ERα localization to ERα-target genes, regardless of tamoxifen sensitivity. However, this observation is
also consistent with decreased ERα levels following talazoparib treatment. Further experimentation will
be necessary to understand the exact mechanism of talazoparib-mediated decrease in ERα localization to
ERα-target genes.
In terms of a mediator of both tamoxifen and PARPi response, here we identify miR-222 as
a potential negative regulator of tamoxifen-talazoparib mediated cell death. Tamoxifen resistant
breast cancers overexpress miR-222 [39,40], and oxidative damage increases miR-222 expression.
Interestingly, through inhibition of DSB damage repair, miR-222 overexpression is sufficient to promote
PARPi sensitivity in ovarian cancer cells [38]. Beyond validating miR-222 overexpression in tamoxifen
resistant cells, this is the first demonstration that upregulation of miR-222 increases PARP1 activation
and PARPi sensitivity and decreases RAD51 foci formation in breast cancer cells. By inhibiting
the oncomir (oncogenic miRNA), we further show the importance of miR-222 as a mediator of
tamoxifen-talazoparib efficacy. Collectively, the data support a critical role for miR-222 in mediating
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response to tamoxifen-talazoparib treatment, with both loss and gain of miR-222 expression regulating
response to single agent tamoxifen or talazoparib.
While the present study focuses on a proposed mechanism to overcome tamoxifen resistance
through combination with PARPi, we do not believe this to be a mutually exclusive mechanism of
induced cell death. In addition to PARPi-mediated tamoxifen response, our results also demonstrate a
novel mechanism to overcome PARPi resistance, regardless of BRCA status, as all cell lines examined
are BRCA-proficient and do not respond to PARPi as a single agent. Tamoxifen increases ROS and
miR-222 expression but does not increase homologous recombination repair (RAD51 foci), all of which
represent therapeutic avenues to increase sensitivity to PARPi [19,38,45], suggesting a novel feedback
loop such that both tamoxifen increases sensitivity to PARPi and PARPi to tamoxifen.
Additionally, work by our group and Muvarak et al. demonstrate that addition of talazoparib to cells
promotes PARP1 trapping to DNA, increases DNA damage and ultimately cell death in combination with
DNMT inhibitors [29,46]. ROS induces several classes of DNA damage to which PARP1 may localize,
and talazoparib is the most potent PARP1 trapper [32]. It is conceivable that tamoxifen-mediated
ROS accumulation and co-administration with talazoparib promotes trapping of PARP1 to DNA,
enhancing the efficacy of tamoxifen-talazoparib co-administration. In support of this possibility, we
demonstrate that tamoxifen co-administration with the PARPi veliparib, a less potent PARP-trapper, was
able to induce cell death but not to the extent of the tamoxifen-talazoparib combination treatment [32].
Moreover, we show tamoxifen-talazoparib co-administration reduces nuclear localization of both ERα
and PARP1, though some PARP1 remains in the nucleus (Supplemental Figure S3). Talazoparib robustly
reduces ERα at ERE sites and PARP1 but to a much lesser extent (Figure 4), indicating that PARP1
may be more tightly bound to the DNA (albeit not directly explored in this study). It is important to
note that differences in ChIP enrichment at ERE sites may be due to either altered ERα and PARP1
nuclear localization, as demonstrated (Supplemental Figure S3), or decreased DNA affinity in the
absence of PARP1 activity [27]. Further studies are needed to discriminate between these mechanisms.
Nonetheless, it seems reasonable to suggest that some of the enhanced response to tamoxifen-talazoparib
co-administration is a result of tamoxifen-mediated ROS accumulation and PARP1 trapping.
In summary, using a model system based on the MCF7 breast cancer cell line, we show addition
of a PARPi increases cell response to tamoxifen in tamoxifen-resistant ERα+ breast cancer. We put
forth a model of tamoxifen-mediated ROS accumulation, which increases miR-222 expression and
subsequently PARP1 activity, priming the cell towards tamoxifen sensitivity, in an ERα-dependent
manner (Supplemental Figure S6) and in the context of intact BRCA. Collectively, these data support
additional pre-clinical and clinical investigation of tamoxifen-talazoparib combination for patients
with tamoxifen resistant ERα+ breast cancer. Our future studies aimed at better understanding the
significance of ERα PARylation and increasing the translational impact of the therapeutic combination
will include multiple cell lines and in vivo model systems.
4. Materials and Methods
4.1. Cell Lines, Culture Conditions and Reagents
MCF7 and anti-estrogen resistant derivatives (MCF7-T and MCF7-F) were maintained and
established as we have previously described [30]. Briefly, MCF7-T cells were maintained in
tamoxifen-containing media, except prior to drug treatment. The maintenance concentration of
tamoxifen was 100 nM. MCF7/LCC2 and MCF7/LCC9 cells lines (anti-estrogen resistant) were
derived and maintained as described by Brünner et al. [33]. Cell lines were authenticated in
2017 by ATCC and tested for mycoplasma contamination (Manassas, VA, USA). To ensure cell
line integrity, all cell lines were thawed at frequent intervals and not used beyond 30 passages.
Additionally, cell morphology was monitored for each cell line, and proper media and growth
conditions selected [29,30]. Hydrogen peroxide (H2O2) was purchased from EMD Millipore
(Billerica, MA, USA). Tamoxifen (Tamox or 4-OHT) was purchased from Sigma Aldrich (St. Louis,
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MO, USA). Talazoparib (Talaz; PARPi) was provided by Pfizer/Medivation (San Francisco, CA,
USA). Primary antibody dilutions were as followed: PARP1 (Cell Signaling, Danvers, MA, USA;
1:3000), PAR (Trevigen, Gaithersburg, MD, USA; 1:2000) ERα (Santa Cruz, Dallas, TX, USA; 1:2000),
pERBB2 (Cell Signaling; 1:2000), GAPDH (Santa Cruz; 1:2000), IgG (Santa Cruz; 1:5000), β-Tubulin
(Santa Cruz; 1:5000).
4.2. Clonogenic Survival and MTT Assay
Cells were seeded to 60–70% confluence in 10 cm plates and treated for the indicated times.
24 h following treatment, cells were washed, serially diluted, and plated in triplicate on 6-well plates
(500–1000 cells/well). 6–14 days of cell growth were allowed for colony formation, followed by
staining with 0.5% crystal violet. Cell counts were normalized to untreated controls as previously
described [47]. Combination treatment scheme is as followed: Co-administration (‘Co-ad’) with both
100 nM tamoxifen (Tamox) and 1 nM talazoparib (Talaz) on day 1, and 100 nM Tamox on days 2 and 3,
unless otherwise indicated.
4.3. RNA Extraction, Quantitative RT-PCR and Cell Transfection
RNA was extracted via RNeasy kit (Qaigen, Venlo, Limburg, The Netherlands), and cDNA
prepared with MMLV reverse transcriptase (Promega, Madison, WI, USA). qRT-PCR was performed
as we have previously described [48], using EEF1A as the internal control. Cells were treated with
either miR-222 mimic (Ambion, Carlsbad, CA, USA; 4464066) or miR-222 inhibitor (Ambion; AM17000)
within the indicated treatments conditions and according to the manufacturer’s protocol using the
Lipofectamine 3000 reagent (Thermo Fisher Scientific, Waltham, MA, USA; L3000008).
4.4. PAR-Capture ELISA
Confluent (80%) 10 cm plates were treated as described in the text. Following treatment, samples
were harvested, 20% SDS was added (to a final concentration of 1%), protein concentration measured
according to the manufacturer’s protocol (Trevigen; 4520-096-K) and the lysate was snap-frozen and
placed at−80 ◦C. Preparation of the PAR standard curve and treated samples was performed according
to the manufacturer’s protocol, and as we have described [29]. In brief, 100 µL (20 µg protein) of
each sample was added to a 96-well plate, pre-coated with PAR capture antibody and allowed to
incubate overnight. Wells were then washed with PBST (PBS + 0.1% Tween 20) and incubated with
primary antibody (PAR Polyclonal antibody), washed with PBST and incubated in secondary antibody
(Goat Anti-Rabbit IgG HRP). Plates were washed with PBST, chemiluminescent substrate was added,
and luminescence measured. The data are reported as the relative change in PAR concentration
compared to control.
4.5. ROS Assays
Confluent 10 cm plates were treated as indicated in the text. Following treatment,
2 × 104 cells/well were plated on 96-well plates. 24 h post plating, ROS assay, measuring H2O2
levels, (Promega) was performed as previously described [47].
4.6. Immunofluorescence
Cells were treated as described and plated on glass slides (50,000 cells/well), fixed and
permeabilized as described by Sakai et al. [49]. Following permeabilization, cells were incubated for 1
h with RAD51 antibody (1:1000), γH2Ax antibody (1:1000), or 8-hydroxyguanosine (8-oxoG) (1:1000).
Secondary antibody (Invitrogen, Carlsbad, CA, USA) was added and slides incubated for 45 min.
Nuclei were counterstained with Hoechst stain (1:5000; 33342, Invitrogen). Images were captured
using a Nikon NIE microscope, and processed using NIS Elements Viewer. Cells with 5 or more RAD51
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foci were considered positive (per ref [49]) and cells with 20 or more γH2Ax foci were considered
positive. Results are representative of three independent experiments ± SEM.
4.7. Western Blot Analysis
Total cell lysate was prepared with RIPA lysis buffer. Western blot analysis was performed as we
have described previously [47].
4.8. Combination Index and Synergism
Cells were treated and plated as indicated for clonogenic survival assays (500 cells/well).
Following treatment, percent survival subtracted from 100% was indicative of the fraction affected (FA).
Subsequent combination indices, and synergism determination, were determined by the Chou-Talalay
method ([31]; with mutually non-exclusive assumption) using CompuSyn Software [50].
4.9. Immunoprecipitation Assays
MCF7 and MCF7-T cells were grown to confluence (90%) in 15 cm plates, and treated as
described in the text. 24 h following treatment, cells were washed with PBS and harvested in
immunoprecipitation (IP) lysis buffer and protease inhibitors. The lysate was sonicated briefly and
rotated at 4 ◦C, followed by centrifugation at 13,000 rpm for 10 min. The lysates were added to
50–60 µL of pre-conjugated protein A/G beads with the indicated antibodies. Beads were pelleted
(1000 rpm, 4 ◦C) and washed in IP buffer. The samples were run on SDS-PAGE gel and immunoblot
analysis was performed against the indicated antibodies [4,47].
4.10. Chromatin Immunoprecipitation (ChIP)-qPCR
MCF7 and MCF7-T cells were grown to confluency (90%) in 15 cm plates, and treated as described
in the text. 24 h following treatment cells were washed with PBS, crosslinked with 10% formalin and
harvested in immunoprecipitation (IP) lysis buffer. Following IP (previously described, [48]) with
antibody pre-conjugated protein agarose beads, the crosslinks were reversed, and DNA was purified.
ChIP-qPCR primers targeting the estrogen response element (ERE) were designed as previously
described by Jin et al. [4]. A negative control region was used, as we have previously described [48].
4.11. Statistical Analysis
All data, unless noted otherwise, are represented as mean value ± SEM of at least three
biological replicates. IC50 data was determined by Prism 6 (GraphPad Software, San Diego,
CA, USA), using logarithm normalized sigmoidal dose-curve fitting. Tukey’s test for multiple
comparisons correction was used to analyze the significance among different groups in biological
assays, unless otherwise stated. For in vivo experiments, ANOVA/Mann-Whitney tests (GraphPad)
were used to determine statistical significance, as described [46].
5. Conclusions
Therapeutic targeting of ERα by tamoxifen is standard of care for premenopausal breast
cancer. While tamoxifen increases overall survival, tamoxifen resistance remains a major limitation,
despite continued expression of ERα in resistant tumors. Towards a better molecular understanding
of endocrine resistance, we used clonally derived ERα-positive, antiestrogen-resistant breast cancer
MCF7-cell models and demonstrated differential ERα PARylation in tamoxifen-resistant vs. –sensitive
cells. We further demonstrated that tamoxifen treatment was sufficient to activate PARP and increase
ERα PARylation in an ROS-dependent manner. Combination treatment of the PARP inhibitor
talazoparib with tamoxifen effectively blocked ERα PARylation, markedly decreased ERα localization
to ERα target genes and significantly enhanced response to tamoxifen in an ERα-dependent manner in
models of acquired tamoxifen resistance. We provide the first pre-clinical evidence that combining
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a PARP inhibitor with tamoxifen has significant activity against tamoxifen-resistant breast cancers
which continue to express ERα, a therapeutic strategy that may warrant further investigation.
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